Literature DB >> 25840382

Selection of optimal tobacco cessation medication treatment in patients with cancer.

Rosario Wippold1, Maher Karam-Hage1, Janice Blalock1, Paul Cinciripini2.   

Abstract

BACKGROUND: Tobacco use is responsible for almost half a million deaths per year in the United States, and it accounts for one-third of all cancer deaths. Limited data concerning tobacco treatment among patients with cancer are available. In addition, these patients often have complicated medical histories and are taking multiple medications. No clear, published procedures exist to help the healthcare provider select the proper medication for tobacco cessation in that context.
OBJECTIVES: This article describes the screening process established within the Tobacco Treatment Program (TTP) at the University of Texas MD Anderson Cancer Center to minimize the risk of prescribing a contraindicated tobacco cessation medication to patients with cancer. The screening process developed and used by the TTP is presented as a viable model for selecting appropriate tobacco cessation medications for patients with cancer.
METHODS: The electronic medical record of each patient who uses tobacco is carefully reviewed once he or she is scheduled for a consultation. A summary is produced with a standardized template and used later as a template for the medical provider evaluation. Precautions are put in place with consideration of the characteristics of each of the tobacco cessation medications (e.g., mechanism of action, route of administration, interactions with other medications, possible side effects, contraindications). Since 2006, the TTP has had more than 4,000 new patients and more than 39,000 follow-up visits.
FINDINGS: Because each patient with cancer has unique medical, psychological, and social circumstances, the process of selecting the optimal tobacco cessation medication needs to be individualized. Oncology healthcare providers should follow some form of screening to tailor a medication plan to each patient.

Entities:  

Keywords:  bupropion; cancer; nicotine replacement therapies; tobacco cessation; tobacco treatment; varenicline

Mesh:

Year:  2015        PMID: 25840382      PMCID: PMC6029249          DOI: 10.1188/15.CJON.170-175

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  12 in total

1.  Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.

Authors:  Serena Tonstad; Simon Davies; Martina Flammer; Cristina Russ; John Hughes
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

2.  Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.

Authors:  Serena Tonstad; Philip Tønnesen; Peter Hajek; Kathryn E Williams; Clare B Billing; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

3.  Smoking prevalence and cigarette consumption in 187 countries, 1980-2012.

Authors:  Marie Ng; Michael K Freeman; Thomas D Fleming; Margaret Robinson; Laura Dwyer-Lindgren; Blake Thomson; Alexandra Wollum; Ella Sanman; Sarah Wulf; Alan D Lopez; Christopher J L Murray; Emmanuela Gakidou
Journal:  JAMA       Date:  2014-01-08       Impact factor: 56.272

4.  Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Authors:  J T Hays; R D Hurt; N A Rigotti; R Niaura; D Gonzales; M J Durcan; D P Sachs; T D Wolter; A S Buist; J A Johnston; J D White
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

5.  Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.

Authors:  M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

Review 6.  Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.

Authors:  Henri-Jean Aubin; Amandine Luquiens; Ivan Berlin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 7.  Varenicline: a novel pharmacotherapy for smoking cessation.

Authors:  Carlos Jiménez-Ruiz; Ivan Berlin; Thomas Hering
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

Review 8.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

Review 9.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.

Authors:  Judith J Prochaska; Joan F Hilton
Journal:  BMJ       Date:  2012-05-04

10.  Current cigarette smoking among adults - United States, 2005-2012.

Authors:  Israel T Agaku; Brian A King; Shanta R Dube
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-01-17       Impact factor: 17.586

View more
  3 in total

1.  Panic attacks and smoking cessation among cancer patients receiving smoking cessation treatment.

Authors:  Samantha G Farris; Jason D Robinson; Michael J Zvolensky; Julianna Hogan; Vance Rabius; Paul M Cinciripini; Maher Karam-Hage; Janice A Blalock
Journal:  Addict Behav       Date:  2016-05-13       Impact factor: 3.913

2.  Identifying Best Implementation Practices for Smoking Cessation in Complex Cancer Settings.

Authors:  Eleni Giannopoulos; Janet Papadakos; Erin Cameron; Janette Brual; Rebecca Truscott; William K Evans; Meredith Elana Giuliani
Journal:  Curr Oncol       Date:  2021-01-13       Impact factor: 3.677

3.  The Impact of Treatment for Smoking on Breast Cancer Patients' Survival.

Authors:  Akshara Singareeka Raghavendra; George Kypriotakis; Maher Karam-Hage; Seokhun Kim; Mazen Jizzini; Kareem S Seoudy; Jason D Robinson; Carlos H Barcenas; Paul M Cinciripini; Debu Tripathy; Nuhad K Ibrahim
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.